Sigma Pharmaceuticals Forecast, price target & analysts
Sigma Pharmaceuticals Target price 2025 - Analyst rating & recommendation
Sigma Pharmaceuticals Classifications & Recommendation:
Sigma Pharmaceuticals Price Target
| Target Price | AUD2.74 |
| Price | AUD3.07 |
| Deviation |
10.75%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Sigma Pharmaceuticals 2026 .
The average Sigma Pharmaceuticals target price is AUD2.74.
This is
10.75%
register free of charge
AUD3.30
7.49%
register free of charge
AUD1.95
36.48%
register free of charge
|
|
| A rating was issued by 8 analysts: 2 Analysts recommend Sigma Pharmaceuticals to buy, 3 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sigma Pharmaceuticals stock has an average upside potential 2026 of
10.75%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Jan '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion AUD | 4.93 | 8.64 |
| 44.14% | 78.42% | |
| EBITDA Margin | 0.96% | 11.96% |
| 36.09% | 1,936.37% | |
| Net Margin | -0.32% | 1.07% |
| 428.96% |
6 Analysts have issued a sales forecast Sigma Pharmaceuticals 2026 . The average Sigma Pharmaceuticals sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Sigma Pharmaceuticals EBITDA forecast 2026. The average Sigma Pharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Sigma Pharmaceuticals Analysts have issued a net profit forecast 2026. The average Sigma Pharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Jan '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share AUD | -0.01 | 0.06 |
| 700.00% | ||
| P/E | 51.57 | |
| EV/Sales | 4.04 |
4 Analysts have issued a Sigma Pharmaceuticals forecast for earnings per share. The average Sigma Pharmaceuticals EPS is
This results in the following potential growth metrics and future valuations:
Sigma Pharmaceuticals...
Current Sigma Pharmaceuticals Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ORD MINNETT |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| MACQUARIE RESEARCH |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| SHAW AND PARTNERS |
Locked
➜
Locked
|
Locked | Aug 28 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
ORD MINNETT:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
MACQUARIE RESEARCH:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
SHAW AND PARTNERS:
Locked
➜
Locked
|
Aug 28 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
